Wound healing remains a global issue of disability, cost, and health. Addition of cells from the stromal vascular fraction (SVF) of adipose tissue has been shown to increase the rate of full thickness wound closure. This study aimed to investigate the angiogenic mechanisms of CD2481 SVF cells in the context of full thickness excisional wounds. Single cell transcriptional analysis was used to identify and cluster angiogenic gene-expressing cells, which was then correlated with surface marker expression. SVF cells isolated from human lipoaspirate were FACS sorted based on the presence of CD248. Cells were analyzed for angiogenic gene expression and ability to promote microvascular tubule formation in vitro. Following this, 6mm full thickness dermal wounds were created on the dorsa of immunocompromised mice and then treated with CD2481, CD248-, or unsorted SVF cells delivered in a pullalan-collagen hydrogel or the hydrogel alone. Wounds were measured every other day photometrically until closure. Wounds were also evaluated histologically at 7 and 14 days post-wounding and when fully healed to assess for reepithelialization and development of neovasculature. Wounds treated with CD2481 cells healed significantly faster than other treatment groups, and at 7 days, had quantitatively more reepithelialization. Concurrently, immunohistochemistry of CD31 revealed a much higher presence of vascularity in the CD2481 SVF cells treated group at the time of healing and at 14 days post-op, consistent with a pro-angiogenic effect of CD2481 cells in vivo. Therefore, using CD2481 pro-angiogenic cells obtained from SVF presents a viable strategy in wound healing by promoting increased vessel growth in the wound.
ABSTRACT
Wound healing remains a global issue of disability, cost, and health. Addition of cells from the stromal vascular fraction (SVF) of adipose tissue has been shown to increase the rate of full thickness wound closure. This study aimed to investigate the angiogenic mechanisms of CD2481 SVF cells in the context of full thickness excisional wounds. Single cell transcriptional analysis was used to identify and cluster angiogenic gene-expressing cells, which was then correlated with surface marker expression. SVF cells isolated from human lipoaspirate were FACS sorted based on the presence of CD248. Cells were analyzed for angiogenic gene expression and ability to promote microvascular tubule formation in vitro. Following this, 6mm full thickness dermal wounds were created on the dorsa of immunocompromised mice and then treated with CD2481, CD248-, or unsorted SVF cells delivered in a pullalan-collagen hydrogel or the hydrogel alone. Wounds were measured every other day photometrically until closure. Wounds were also evaluated histologically at 7 and 14 days post-wounding and when fully healed to assess for reepithelialization and development of neovasculature. Wounds treated with CD2481 cells healed significantly faster than other treatment groups, and at 7 days, had quantitatively more reepithelialization. Concurrently, immunohistochemistry of CD31 revealed a much higher presence of vascularity in the CD2481 SVF cells treated group at the time of healing and at 14 days post-op, consistent with a pro-angiogenic effect of CD2481 cells in vivo. Therefore, using CD2481 pro-angiogenic cells obtained from SVF presents a viable strategy in wound healing by promoting increased vessel growth in the wound.
Cells within the stromal vascular fraction (SVF) have been extensively studied in the context of promoting diabetic wound healing, 1 enhancing fat graft retention in irradiated and nonirradiated settings, 2, 3 and for reconstruction of calvarial defects. 4 However, the exact mechanisms of action of these transplanted cells in regenerating tissue/restoring damage are not fully known. It can be postulated that the stemness of this population leads to differentiation into the target tissue through influence of the local microenvironment. It is also known, although, that implanted cells can deliver growth factors in a paracrine fashion. 5, 6 Secreted factors by SVF cells have been shown to induce tubule formation in vitro by human microvascular endothelial cells. 7 Importantly, the heterogeneity of SVF cells has limited the ability for precise, unambiguous delineation of cellular function, particularly with bulk population transcriptional analyses. This heterogeneity also poses a significant challenge for use of these cells in translational applications. Subpopulations within SVF cells have been documented with disparate biologic activity and potentials for lineage differentiation, and this carries important therapeutic implications for clinical use where efficacy and reproducibility is key. Recent development of single-cell transcriptional assays has begun to yield meaningful information regarding biologic function of individual cells, and this has guided selection of novel subpopulations for various purposes. [8] [9] [10] [11] Microfluidic single cell analysis allows for evaluation of transcriptional profiles of multiple individual cells, which can facilitate identification and isolation of pro-angiogenic subpopulations using flow cytometry. Microfluidic analysis of cells within the SVF has already proven useful in identifying cell surface markers indicating pro-osteogenic cell populations. Through this approach, subpopulations isolated based on CD105, CD90, or BMPR-IB expression have all been shown to enhance bone regeneration in an in vivo mouse calvarial defect model. 9, 12, 13 It is thus possible to interrogate a heterogeneous cell population and cluster the transcriptional data output based on specific gene expression, 14 and organization of cell phenotypes by proxy of expressed genes can allow for recognition and isolation of desired subpopulations within a larger heterogeneous mix.
In this study, a bioinformatics approach to examine proangiogenic cells via gene expression profiles (VEGF, FGF2, PDGFRa, and PDGFRb) was employed, and we identified CD248 as a significantly expressed surface marker among cells with high levels of angiogenic gene transcripts. We then investigated the in vitro gene expression profile of CD2481 cells and their ability to promote tubule formation by human microvascular endothelial cells. Having determined the efficacy of this population in vitro, we finally investigated the potential of CD2481 cells to contribute to faster wound healing in vivo.
MATERIALS AND METHODS

Human adipose-derived SVF harvest
Human lipoaspirate specimens from the abdomen were obtained from five healthy female donors following informed consent under Stanford Institutional Review Board approval (Protocol No. 2188). Donors were between the ages of 35-50 and had no medical comorbidities. The lipoaspirate was processed to obtain SVF cells. Briefly, the lipoaspirate was washed twice with phosphate-buffered saline (PBS) and then digested using type II collagenase (Sigma-Aldrich; St. Louis, MO) in Medium 199 (Cellgro; Manassas, VA) at 37 8C under gentle agitation for 30 minutes. Digestion was neutralized with an equal volume of Dulbecco's Modified Eagle's Medium plus GlutaMAX (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) and centrifuged at 1,500 r.p.m. for 20 minutes. The supernatant was aspirated and the cell pellet was resuspended in DMEM and then passed through a 100 lm pore cell strainer (Corning, Corning, NY) before being re-centrifuged at 1,500 r.p.m. for 15 minutes. The cell pellet was resuspended in red cell lysis buffer and centrifuged again at 1,500 r.p.m. for 15 minutes, leaving a SVF pellet. The number of live SVF cells were counted using trypan blue.
Microfluidic chip-based single cell analysis
Microfluidic chip-based single cell transcriptional analysis was performed as previously described. 11, [15] [16] [17] [18] Single cells were sorted into each well of a 96-well plate, which was preloaded with 10 ll of a master mix containing Tris-EDTA buffer (pH 7.0), Superscript III reverse transcriptase enzyme (Invitrogen), Cells Direct reaction mix (Invitrogen), target gene-specific TaqMan assay (primer/probe) sets (Applied Biosystems, Foster City, CA), and SUPERase-In RNAse inhibitor (Applied Biosystems). Exon-spanning primers were selected to avoid amplification of genomic background. Cells were then lysed and reverse transcription was performed (20 minutes at 50 8C, 2 minutes at 95 8C), followed by gene-specific amplification of the cDNA (22-cycles, 95 8C for 15 minutes then 60 8C for 4 minutes). Resultant amplified single cell cDNA was then mixed with sample loading agent (Fluidigm, South San Francisco, CA) and Universal PCR Master Mix (Applied Biosystems) and placed into individual wells of 48.48 Dynamic Array chips (Fluidigm). TaqMan probes and assay loading agent were also placed into individual wells according to the manufacturer's instructions (Fluidigm). Products were analyzed on the BioMark reader system (Fluidigm) using a hot start protocol, and 30 quantitative PCR cycles were performed. 18 
Surface marker correlation
Expression data from microfluidic chips were normalized relative to median expression for each gene and converted to base 2 logarithms. A Fuzzy C-Means clustering algorithm was employed to cluster groups of cells based on similarities in gene expression. 9, 18 Cluster designations were then flattened to assign each cell the single cluster for which it associated the highest membership, thus creating two mutually exclusive sets. Linear discriminant analysis was applied to determine genes whose expression patterns maximally differed between the two groups and a receiver operating characteristic analysis was used to create a feature subset of genes with corresponding partition function (VEGF, FGF2, PDGFRA, and PDGFRB). Finally, linear discriminant analysis was employed to identify surface marker genes whose expression was best able to distinguish between the two groups.
9,18
FACS isolation of CD248 cell populations
Freshly harvested SVF cells from lipoaspirate were resuspended in FACS buffer (1XPBS, 2% FBS, 1% P188, 1% Pen-Strep, Gibco), and were stained with anti-CD248 antibody (human anti-CD248 primary antibody, ab115870 at 1 : 100, Abcam, Cambridge, UK). Flow cytometry was used to quantify the proportion of SVF cells which express CD248. Positive and negative populations were then sorted using a FACS Aria II (BD Biosciences, San Jose, CA) with a 100 lm nozzle.
Angiogenic gene expression
RNA for gene expression assay was collected at day 0, from fresh SVF cells, harvested using TRIzol (Life Technologies) and processed using the RNeasy Mini Kit (Qiagen; Hilden, Germany). Reverse transcription was performed using TaqMan Reverse Transcription Reagents (Invitrogen). An ABI Prism 7900HT Sequence Detection System (Applied Biosystems) was used to perform quantitative real-time polymerase chain reaction (qRT-PCR) with Power SYBR Green PCR Master Mix (Applied Biosystems) as the reporter. qRT-PCR analysis was conducted to detect gene expression levels of pro-angiogenic hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF). Expression levels of all genes were normalized to GAPDH expression values.
In vitro endothelial tube formation assay
To further explore the proangiogenic effect of CD2481 SVF cells, an endothelial tubule formation assay was performed. Human microvascular endothelial cells were seeded at a density of 1.2 3 10 5 cells per well on Geltrexcoated 24-well plates in unsupplemented endothelial cell media (Thermo Fisher, Waltham MA). FACS-sorted CD2481 and CD248-cell populations and unsorted SVF cells were seeded in cell culture inserts at a density of 7.5 3 10 3 cells per insert. As a control, endothelial cells were also treated with 10 ng/ml recombinant VEGF alone. Endothelial cells were incubated for 18 hours and stained with Calcein AM immediately before imaging. Tubule analysis was performed with the Angiogenesis Analyzer tool for ImageJ which measures the total area of tube formation/mesh area, master segments which consist of pieces of the network delimited by two junctions, and master junctions which are intersections linking at least three master segments in each field of view.
In vivo full thickness dorsal wounds
All experiments were performed in accordance with the Stanford University Animal Care and Use Committee Guidelines and approved APLAC protocols. Two 6 mm full thickness wounds were made at the same level on the dorsum of CD1 athymic nude mice, as previously described. 19 A silicone 12 mm diameter washer (Invitrogen) was placed around the perimeter of the wound and secured with cyanoacrylate glue and interrupted Ethilon 6-0 sutures (eSutures.com, Mokena, IL) to prevent wound contracture. Mice were randomized into four groups (n 5 11 animals per group, thus 22 wounds per group) receiving different treatments including: pullalan-collagen hydrogel alone, unsorted SVF cells, CD248-SVF cells, or CD2481 SVF cells in a pullalan-collagen hydrogel. A total of 250,000 cells were added to each wound with 20 ll of PBS. The hydrogel alone received 20 ll of PBS as a vehicle control. Wounds were dressed with Tegaderm sterile dressing (3M Healthcare, St Paul, MN), which was changed post-op day 3, followed by every other day until wound closure. For each treatment group, mice were sacrificed in three different time points; three mice at day 7, three mice at day 14, and five mice at the day of closure for each specific group. Digital photographs were taken at the time of surgery and every dressing change until closure, defined as the time at which the wound bed was completely reepithelialized and filled with new tissue. Wound area was quantified using ImageJ software (NIH, Bethesda, MD) and expressed as a ratio of wound circumference to silicone stent circumference.
Histological analysis of wounds
Mice were sacrificed and dorsal skin was harvested for histological analysis at either day 7, 14, or at time of wound healing. Briefly, skin was fixed in 4% paraformaldehyde and subsequently dehydrated and embedded for paraffin sectioning. Sections were cut at 8 /m and immunohistochemical staining was used at 7 days to assess levels of VEGF and CD248 in the nonhealed wounds (anti-mouse VEGF, ab46154 at 1 : 50, and CD248 primary antibody, ab115870 at 1 : 50, Abcam). Tissue harvested on day 7 was also sectioned, H&E stained, and epithelialization was assessed from slides at the center of the wound as a percentage of the original wound (n 5 10 sections per wound). At day 14, and at wound closure per group, CD31 staining was performed to assess vasculature (anti-mouse CD31 primary antibody, ab28364 at 1 : 50, Abcam), and CD248 and VEGF stains were also performed to assess early pro-angiogenic changes in the extracellular matrix.
Statistical analyses
Data are presented as means 6 standard deviation (SD). Analyses of variance (ANOVA) were used for multiple group comparisons. A *p-value of < 0.05 was considered to be statistically significant. All statistical analyses were performed using GraphPad Prism software (GraphPad Software Inc.; La Jolla, CA). For single-cell transcriptional data, a Kolmogorov-Smirnov test was used to compare empirical distributions, followed by an adaptive Fuzzy C-Means clustering algorithm as described above. 18 
RESULTS
CD248 is expressed by cells which secrete VEGF
Within the heterogeneous population of SVF cells in lipoaspirate, microfluidic single cells expression analysis identified a subpopulation of cells with increased expression of angiogenic genes. Using a nonparametric Kolmogorov-Smirnov test and receiver operating characteristic analysis, SVF cells could be assigned membership into one of two clusters based on expression of multiple angiogenic genes (VEGF, FGF2, PDGFRA, and PDGFRB) ( Figure  1A ). Linear discriminant analysis was then performed to correlate cell surface marker expression with the angiogenic SVF cell population in question, and a significant correlation between CD248 expression and clustering of SVF cells based on angiogenic gene expression was noted ( Figure 1B ) (*p < 0.05). FACS analysis revealed that SVF was 14.8% positive for CD248 ( Figure 1C ).
CD2481 cells express significantly higher proangiogenic genes, and induce higher quantities of robust tubules in vitro
Gene expression analysis was performed for HGF and VEGF on CD2481/-and unsorted cells. CD2481 cells were found to express significantly elevated levels of HGF and VEGF in comparison to CD248-SVF cells and unsorted SVF cells (*p < 0.05, **p < 0.01) (Figure 2A ). CD2481 SVF cells also enhanced the ability of human microvascular endothelial cells to form tubules in vitro. Specifically, CD2481 SVF cells induced a statistically significant increase in the total area of tube formation (percent mesh area), number of nodes/master junctions, and number of tubules/segments formed by microvascular endothelial cells when compared to CD248-and unsorted SVF cells (*p < 0.05) ( Figure 2B and C) . Furthermore, the effects of CD2481 SVF cells on endothelial cells were similar or greater than that observed with exogenous VEGF control.
CD2481 cells lead to faster healing of wounds with more vascularity
To evaluate the ability of SVF cell subpopulations to enhance wound healing, bilateral full thickness excisional wounds were created on the dorsa of immunocompromised mice. Each wound was then supplied with a pullalan-collagen hydrogel, and subsequently treated with either CD2481 cells, CD248-cells, unsorted cells, or no cells (hydrogel alone). By 13 days post-wounding, animals which received CD2481 cells healed completely, in contrast to complete healing noted at day 15 for CD248-and unsorted cell groups, and 16 days for the group which did not receive cells ( Figure 3A) . Using Image J analysis for wound area, it was seen that the group which received CD2481 cells had significantly more healing than all other groups (CD248-, unsorted cells, and hydrogel alone) by day 7, a pattern which continued through day 9 and day 11 (*p < 0.05 for CD2481 vs. all other groups at all three time points) ( Figure 3B ). Wounds harvested at day 7 demonstrated greater VEGF and CD248 staining in the CD2481 group when compared to the CD248-, unsorted, and hydrogel alone groups ( Figure 4A ), and these differences were found to be significant ( Figure 4B ) (*p < 0.05). While CD31 staining at 7 days post-op showed no significant differences ( Figure  5A and bottom of Figure 5C ), H&E staining of the entire wound showed keratinocyte migration over the wounded dermis to be greatest when treated with CD2481 cells compared to the other three groups ( Figure 5B and top of Figure 5C ). Wounds were also analyzed at 14 days post-op across all groups ( Figure 6A ). Significantly more CD31 staining was found between the wounds treated with CD2481 cells when compared to the remaining three groups ( Figure 6B ) (*p < 0.05). Once wounds were fully healed, the remaining mice were sacrificed and wounds were harvested for immunohistochemistry analysis and H&E staining ( Figure 6C ). At this later timepoint, anti-CD31 staining again revealed significantly higher percentage of positive staining in the CD2481 group when compared to the remaining groups ( Figure 6D ) (*p < 0.05).
DISCUSSION
CD248, also known as endosialin and tumor endothelial marker 1 (TEM-1), does not have a fully characterized role, which is reflected in some conflicting literature. While some describe CD248 as a marker of tumor related myofibroblasts, 20 it has also been described as a marker of stromal fibroblasts, which is not exclusively expressed on tumor endothelium. 21 Furthermore, endosialin expression has also been noted in pericytes, and studies have shown CD248 is necessary for capillary sprouting in skeletal muscle angiogenesis. 22 Endosialin may thus influence angiogenic activity in vivo.
The findings presented here demonstrate the potential of CD248 as a marker of a pro-angiogenic subpopulation of SVF cells, and increased expression of HGF and VEGF among CD2481 SVF cells may contribute to observed enhanced wound healing potential of these cells. VEGF is known to assist wound healing by promoting endothelial cell migration and proliferation, 23 and HGF has also been shown to be an important cytokine for angiogenesis. 24 Furthermore, HGF functions as a hepatotrophic and Quantification of wound area was performed using Image J. Graph represents numeric value of wound area across the four test groups from day 0 until time of wound closure. CD2481 cells are seen to accelerate wound healing significantly compared to CD248-, unsorted cells, and hydrogel alone on days 7, 9, and 11. CD2481 treated wounds healed by day 13, CD248-and unsorted cell-treated wounds healed by day 15, and hydrogel alone-treated wounds healed by day 16 (*p < 0.05 for CD2481 vs. all other groups at days 7, 9, and 11). renotrophic agent for liver and kidney regeneration, 25 and HGF is secreted by dermal fibroblasts as a 90 kDa monomer, which becomes active when proteolytically converted to a heterodimer. 26 Upon wounding, HGF is released from dermal fibroblasts and induces a rapid morphology change in overlying keratinocytes. The change from round, compact cells bound by desmosomal junctions to unbound cells allow them to rapidly cover more surface area, hence helping their role in fast restoration of the integrity of the epithelial barrier. 27 Consistent with this, at our early in vivo time point of 7 days, we observed quantitatively increased migration of keratinocytes in the CD2481 SVF cell treated group. Also observed at 7 days was an increase in VEGF staining in the extracellular matrix of CD2481 SVF cell treated group, which was subsequently associated with increased CD31 staining at the time of wound closure.
The angiogenic effect of CD2481 cells has been demonstrated here in vitro and in vivo. While it is possible that CD2481 SVF cells, suggested by some studies to contain pericytes, 28 may contribute directly to vessel formation themselves, it is also important to note the profound effect their paracrine presence had on endothelial cells within in vitro culture, with a similar or greater proangiogenic effect observed than in our exogenous VEGF positive control. The impact of factors secreted by CD2481 cells (both VEGF and HGF) on the overlying endothelial cell culture helps to explain the significant vascularization the corresponding wound healing exhibited in vivo. 7 Importantly, continued expression of these factors may also contribute to reduced vessel regression during late phases of wound healing, as greater CD31 staining was still appreciated among CD2481 SVF cell treated wounds compared to other groups after healing was noted at day 14.
While it is acknowledged that VEGF acts as a mitogen for endothelial cells through the mechanism of mitogen activated protein kinases (MAPKs), 29 the governance of CD248 expression and how this may relate to angiogenic gene expression remains undefined. Studies have shown that CD248 is associated with developing vasculature, 30 and there is also a link between the expression of CD248 and HIF-2a, a mediator of the hypoxia pathway. CD248 gene expression is driven by a hypoxic response element promoter, leading to its activation in low oxygen pressure environments. 31 CD248 has also been associated with rapid neovascularization in developing fetal tissue. 30 Therefore, the isolation and use of a CD2481 population of cells may enhance angiogenesis within transplanted tissue and hypoxic wound environments.
Importantly, while considering the pro-angiogenic, prohealing impact that CD2481 SVF cells may possess, it is also critical to consider the actual fraction of SVF which is CD2481, as FACS analysis revealed this to be approximately 15%. As SVF cells are known to be remarkably heterogeneous, it is therefore not surprising that unsorted SVF cells provided minimal enhancement of wound healing in our study, as the myriad cell populations comprising the remaining 85% may be neutral or even detrimental to reepithelialization.
Nonetheless, the isolation of a CD2481 subpopulation of SVF cells and use thereof in a wounding model in vivo highlights the ability of these cells to form vasculature and otherwise rescue an area of hypoxic, healing tissue. Therefore, isolating pro-angiogenic cells using this marker may have many potential promising applications where revascularization is necessary. Conversely, studying CD248 also stands to answer some important questions regarding neovascularization, 32 and perhaps may be a marker which can be targeted for tumor treatment.
